NASDAQ:LIXT

Lixte Biotechnology Stock Forecast, Price & News

$3.49

+0.04 (+1.16 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.25

Now: $3.49▼

$3.50

50-Day Range

$3.09

MA: $3.39▼

$4.35

52-Week Range

$3.00

Now: $3.49▼

$7.86

Volume38,761 shs

Average Volume67,789 shs

Market Capitalization$43.19 million

P/E RatioN/A

Dividend YieldN/A

Beta-1.15

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and study with the National Cancer Institute. The company was founded in 2005 and is based in East Setauket, New York.

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1887th out of 1,926 stocks

Pharmaceutical Preparations Industry

761st out of 773 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Lixte Biotechnology.

0.0 Community Rank

Outperform Votes
Lixte Biotechnology has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Lixte Biotechnology has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Lixte Biotechnology and other stocks. Vote “Outperform” if you believe LIXT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LIXT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Lixte Biotechnology does not currently pay a dividend.
Dividend Growth
Lixte Biotechnology does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:LIXT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.lixte.com

Phone631-880-2907

Employees1

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares12,374,000

Market Cap$43.19 million

Next Earnings DateN/A

OptionableNot Optionable

$3.49

+0.04 (+1.16 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive LIXT News and Ratings via Email

Sign-up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.

Lixte Biotechnology (NASDAQ:LIXT) Frequently Asked Questions

How has Lixte Biotechnology's stock been impacted by COVID-19?

Lixte Biotechnology's stock was trading at $0.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LIXT shares have increased by 292.1% and is now trading at $3.49.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Lixte Biotechnology?

Wall Street analysts have given Lixte Biotechnology a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lixte Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Lixte Biotechnology's CEO?

1,448 employees have rated Lixte Biotechnology CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Lixte Biotechnology's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) issued its quarterly earnings data on Friday, November, 4th. The company reported ($0.01) earnings per share for the quarter.
View Lixte Biotechnology's earnings history.

Who are some of Lixte Biotechnology's key competitors?

Some companies that are related to Lixte Biotechnology include Eyenovia (EYEN), DiaMedica Therapeutics (DMAC), Ovid Therapeutics (OVID), Heat Biologics (HTBX), Enlivex Therapeutics (ENLV), Ritter Pharmaceuticals (RTTR), Lumos Pharma (LUMO), vTv Therapeutics (VTVT), FS Development (FSDC), Spring Bank Pharmaceuticals (SBPH), Onconova Therapeutics (ONTX), Orgenesis (ORGS), Cocrystal Pharma (COCP), Genprex (GNPX) and Lipocine (LPCN).
View all of LIXT's competitors.

Who are Lixte Biotechnology's key executives?

Lixte Biotechnology's management team includes the following people:

Dr. John S. Kovach, Founder, Chairman, Pres & CEO (Age 83, Pay $60k)
Mr. Robert Neal Weingarten, VP & CFO (Age 68)
Mr. Eric J. Forman J.D., Chief Admin. Officer (Age 40)
Dr. James S. Miser M.D., Chief Medical Officer (Age 73)
Mr. Gil N. Schwartzberg J.D., Esq., Consultant
Dr. Francis Johnson Ph.D., Consultant

When did Lixte Biotechnology IPO?

(LIXT) raised $7 million in an IPO on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO.

What is Lixte Biotechnology's stock symbol?

Lixte Biotechnology trades on the NASDAQ under the ticker symbol "LIXT."

When did the company's quiet period expire?

Lixte Biotechnology's quiet period expired on Monday, January 4th. Lixte Biotechnology had issued 1,200,000 shares in its initial public offering on November 25th. The total size of the offering was $5,700,000 based on an initial share price of $4.75. During the company's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Lixte Biotechnology?

Shares of LIXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lixte Biotechnology's stock price today?

One share of LIXT stock can currently be purchased for approximately $3.49.

How big of a company is Lixte Biotechnology?

Lixte Biotechnology has a market capitalization of $43.19 million. Lixte Biotechnology employs 1 workers across the globe.

What is Lixte Biotechnology's official website?

The official website for Lixte Biotechnology is www.lixte.com.

How can I contact Lixte Biotechnology?

Lixte Biotechnology's mailing address is 248 ROUTE 25A NO. 2, EAST SETAUKET NY, 11733. The company can be reached via phone at 631-880-2907 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here